U.S. Markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.1281%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.2601%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.4457%)
     
  • BTC-USD

    61,085.34
    +662.73 (+1.10%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection Treatments

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Immunic Inc (NASDAQ: IMUX) has executed an in-license agreement with the University Medical Center Goettingen covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infections (COVID-19 and Influenza).

  • The terms of the agreement were not disclosed.

  • Read Next: Immunic Stock Is Trading Lower After Equity Raise Of M To Fund Lead Pipeline Candidates.

  • Preclinical research recently completed has shown that certain DHODH inhibitors, including Immunic's lead asset, IMU-838, can inhibit SARS-CoV-2 replication in vitro.

  • The Company reiterates its prior guidance that Phase 2 top-line data of IMU-838 in ulcerative colitis is expected in Q2 of 2022.

  • IMU-935 data from the multiple ascending dose part of the Phase 1 trial is expected in Q4 of 2021, with initial clinical data in psoriasis anticipated in Q2 of 2022.

  • The phase 1 trial of IMU-935 in metastatic castration-resistant prostate cancer will start in Q4 of 2021.

  • Enrollment in the Phase 2 CALLIPER trial of IMU-838 in progressive multiple sclerosis will start this month, and Phase 3 ENSURE program of IMU-838 in relapsing-remitting multiple sclerosis in Q4 2021.

  • Related: Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications.

  • Price Action: IMUX shares are down 0.11% at $8.92 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.